Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Economic information and modeling reportBudget impact model

Approach and framework

4 evidence topics · 7 sources

Budget impact model of cretostimogene grenadenorepvec: approach and framework

No evidence found.

Model structures of published cost-effectiveness and cost-per-responder analyses